It’s only fair to share… Ramatroban Formula C21H21FN2O4S CAS 116649-85-5 Mol weight 416.4658 (3R)-3-[[(4-Fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid (+)-(3R)-3-(p-fluorobenzenesulfonamido)-1,2,3,4-tetrahydrocarbazole-9-propionic acid; (+)-3-(4-fluorophenylsulfonamido)-9-(2-carboxyethyl)-1,2,3,4-tetrahydrocarbazole 3-[(3R)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic acid Manufacturers’ Codes: Bay u 3405 3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazole propanoic acid BAY u 3405 BAY u 3406 BAY u-3405 BAY u3405 ramatroban Trademarks: Baynas (Bayer) MF: C21H21FN2O4S MW: 416.47 Percent Composition: C 60.56%, H 5.08%, F …
Tag «BAYER»
Vericiguat, ベルイシグアト
It’s only fair to share… Vericiguat BAY 102; BAY-1021189; MK-1242 1350653-20-1 Chemical Formula: C19H16F2N8O2 Molecular Weight: 426.3878 Vericiguat; 1350653-20-1; UNII-LV66ADM269; Methyl (4,6-diamino-2-(5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)carbamate; BAY-1021189; LV66ADM269 Methyl (4,6-diamino-2-(5-fluoro-1-((2-fluorophenyl)methyl)-1H-pyrazolo(3,4-b)pyridin-3-yl(pyrimidin-5-yl)carbamate methyl N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate Methyl{4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridi- n-3-yl]pyrimidin-5-yl}carbamate Originator Bayer HealthCare Pharmaceuticals Developer Bayer HealthCare Pharmaceuticals; Merck & Co Mechanism of Action Guanylate cyclase stimulants Phase III Chronic heart failure Phase I Coronary artery disease 28 May 2018 Phase …
Copanlisib
It’s only fair to share… Copanlisib, BAY 80-6946, BAY 84-1236 Molecular FormulaC23H28N8O4 Average mass480.520 Da Cas 1032568-63-0 [RN] 1402152-26-4 MONO HCL UNII-WI6V529FZ9 FDA Approved September 2017 2-Amino-N-{7-methoxy-8-[3-(4-morpholinyl)propoxy]-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl}-5-pyrimidinecarboxamide 5-Pyrimidinecarboxamide, 2-amino-N-[2,3-dihydro-7-methoxy-8-[3-(4-morpholinyl)propoxy]imidazo[1,2-c]quinazolin-5-yl]- orphan drug status for follicular lymphoma Copanlisib (BAY 80-6946), developed by Bayer, is a selective Class I phosphoinositide 3-kinase inhibitor[1] which has shown promise in Phase I/II clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia.[2] …